ASCO-CAP guidelines for breast predictive factor testing: an update.
نویسنده
چکیده
This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor and Progesterone Receptor Testing by Immunohistochemistry, published in 2011.
منابع مشابه
Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer
Testing for HER2/neu in breast cancer at the time of primary diagnosis is now the standard of care. Accurate and standardized testing methods are of prime importance to ensure the proper classification of the patient's HER2/neu status. A meeting of pathologists from across Canada was convened to update the Canadian HER2/neu testing guidelines. This National HER2/neu Testing Committee reviewed t...
متن کاملPathologists' Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer.
Expression of the hormone receptors (estrogen receptor (ER) and progesterone receptor (PR)) as well as overexpression / amplification of the human epi-dermal growth factor receptor-2 (HER2) have not only been identified as important prognostic factors among patients with breast cancer. They have also been characterized as essential predictive factors for benefit derivable from endocrine treatme...
متن کاملChromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Chromogenic in situ hybridization (CISH) has shown the potential to replace fluorescence in situ hybridization (FISH) to determine HER2 gene status. To validate the reliability of CISH, we used 226 consecutive breast carcinomas from 2 institutions and tested CISH and FISH on the same tumor set simultaneously at different test sites. Besides manufacturers' scoring criteria, the new American Soci...
متن کاملImpact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
INTRODUCTION The latest guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) to test Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer after being revised in 2008 underwent a second modification in October 2013. The modification includes changes in cut-offs: 10% strong membranous staining for score 3+ on immunohistochemistry (IHC) (p...
متن کاملRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
PURPOSE To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. METHODS ASCO/CAP convened an Update Committee that included coauthors of the 200...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Applied immunohistochemistry & molecular morphology : AIMM
دوره 19 6 شماره
صفحات -
تاریخ انتشار 2011